福元醫藥(601089.SH):藥品製劑研發將堅持“臨牀急需、仿創結合”的研發戰略
格隆匯6月5日丨有投資者向福元醫藥(601089.SH)提問:作為藥械結合的企業,未來短中長期的發展戰略如何;有哪些重點佈局的領域;當前的進展如何?
福元醫藥回覆:公司藥品製劑研發將堅持“臨牀急需、仿創結合”的研發戰略,以仿製藥研發作為當前研發工作核心任務,逐步進入創新藥治療領域;醫療器械領域以臨牀護理產品為主、家用醫療產品為輔進行微創新,並在有條件基礎上進行全方位創新。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.